Cardiometabolic Therapeutics · Prescription Drugs
Esperion: Funding & valuation
Esperion: 0 money records, each linked to its source.
Data updated Nov 22, 2026 · Back to the company report
Financials
Revenue of $403.1M in 2025. +21.3% on the year before. Net income −$22.7M.
$403.1MRevenue2025 · +21.3%
−$22.7MNet income2025 · +56.2%
Revenue by yearas filed, with the net income
Sources: SEC
Money
Esperion: 0 money records, each linked to its source.
Revenue as statedrun rates and months as the company or the press states them; filed results are in Financials
$332.3M
$78.4M
Growth rankingsthe yearly lists of the fastest growing companies
Fastest Growing Companies The Americas 2026
61.8% a year, 2021–2024 · revenue $332.3M in 2024 · 304 employees
Announcedrankings.statista.com ↗
#88
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
